Stefano Vella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8304964/publications.pdf

Version: 2024-02-01

253	19,693	23567 58	11308 136
papers	citations	h-index	g-index

258	258	258	15102
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	27.0	1,560
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
3	Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, The, 1998, 352, 1725-1730.	13.7	1,182
4	Antiretroviral Therapy in Adults. JAMA - Journal of the American Medical Association, 2000, 283, 381.	7.4	951
5	Antiretroviral Therapy for HIV Infection in 1998. JAMA - Journal of the American Medical Association, 1998, 280, 78.	7.4	764
6	Treatment for Adult HIV Infection. JAMA - Journal of the American Medical Association, 2006, 296, 827.	7.4	755
7	A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients. JAMA - Journal of the American Medical Association, 1998, 279, 930.	7.4	694
8	Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. JAMA - Journal of the American Medical Association, 2000, 283, 2417.	7.4	647
9	Antiretroviral Treatment for Adult HIV Infection in 2002. JAMA - Journal of the American Medical Association, 2002, 288, 222.	7.4	632
10	Antiretroviral Drug Resistance Testing in Adults With HIV Infection. JAMA - Journal of the American Medical Association, 1998, 279, 1984.	7.4	528
11	Treatment for Adult HIV Infection. JAMA - Journal of the American Medical Association, 2004, 292, 251.	7.4	482
12	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids, 2005, 19, 593-601.	2.2	472
13	Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. New England Journal of Medicine, 2003, 349, 2293-2303.	27.0	340
14	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	13.7	303
15	SPECT during sleepwalking. Lancet, The, 2000, 356, 484-485.	13.7	300
16	Beyond viral suppression of HIV â€“ the new quality of life frontier. BMC Medicine, 2016, 14, 94.	5.5	279
17	Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet, The, 2013, 381, 2109-2117.	13.7	275
18	Changing incidence of central nervous system diseases in the EuroSIDA cohort. Annals of Neurology, 2004, 55, 320-328.	5.3	273

#	Article	IF	Citations
19	Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya. Journal of Infectious Diseases, 2013, 207, 1359-1369.	4.0	271
20	Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Aids, 1998, 12, 1619-1624.	2.2	237
21	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Societyâ€"Lancet Commission. Lancet, The, 2018, 392, 312-358.	13.7	230
22	Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. New England Journal of Medicine, 2003, 349, 2304-2315.	27.0	218
23	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 325-336.	8.1	208
24	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. Aids, 2008, 22, 2143-2153.	2.2	207
25	High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. Aids, 2001, 15, 1089-1095.	2.2	190
26	Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine, 2003, 4, 255-262.	2.2	181
27	Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. Aids, 2001, 15, 309-320.	2.2	169
28	Factors Influencing Medication Adherence Beliefs and Self-Efficacy in Persons Naive to Antiretroviral Therapy: A Multicenter, Cross-Sectional Study. AIDS and Behavior, 2004, 8, 141-150.	2.7	161
29	Ritonavir-boosted darunavir combined with raltegravir or tenofovirâ€"emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet, The, 2014, 384, 1942-1951.	13.7	158
30	The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. Aids, 1999, 13, 2083-2089.	2.2	156
31	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. Aids, 2012, 26, 1231-1241.	2.2	132
32	Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. Journal of Antimicrobial Chemotherapy, 2007, 60, 724-732.	3.0	124
33	Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. Aids, 2003, 17, 1597-1604.	2.2	110
34	Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. Aids, 2005, 19, 577-583.	2.2	107
35	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrobial Agents and Chemotherapy, 2000, 44, 2109-2117.	3.2	101
36	Gender differences in the treatment of HIV infection. Pharmacological Research, 2008, 58, 173-182.	7.1	89

#	Article	IF	Citations
37	Highâ€Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1â€Infected Persons Does Not Result in Sustained Suppression of Viral Replication. Journal of Infectious Diseases, 1997, 175, 966-970.	4.0	88
38	Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. Aids, 2000, 14, 251-261.	2.2	86
39	Redox Features of the Cell: A Gender Perspective. Antioxidants and Redox Signaling, 2007, 9, 1779-1802.	5.4	86
40	A brief history of antiretroviral therapy of HIV infection: success and challenges. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 44-8.	0.4	85
41	A Randomized Trial of 2 Different 4â€Drug Antiretroviral Regimens versus a 3â€Drug Regimen, in Advanced Human Immunodeficiency Virus Disease. Journal of Infectious Diseases, 2003, 188, 625-634.	4.0	77
42	Mitochondrial Membrane Hyperpolarization Hijacks Activated T Lymphocytes Toward the Apoptotic-Prone Phenotype: Homeostatic Mechanisms of HIV Protease Inhibitors. Journal of Immunology, 2003, 170, 6006-6015.	0.8	74
43	A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. Aids, 1996, 10, 635-642.	2.2	73
44	Antiretroviral therapy: state of the HAART. Antiviral Research, 2000, 45, 1-7.	4.1	71
45	Inductionâ€“maintenance antiretroviral therapy. Aids, 1998, 12, F41-F44.	2.2	70
46	Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. International Journal of Epidemiology, 1997, 26, 400-407.	1.9	69
47	Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine, 2007, 8, 96-104.	2.2	68
48	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. Current HIV Research, 2011, 9, 148-153.	0.5	68
49	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases, 2013, 13, 471.	2.9	68
50	Follow-up on Metabolic Markers in Children Treated for Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 455-460.	5.6	67
51	Saquinavir. Clinical Pharmacokinetics, 1998, 34, 189-201.	3.5	66
52	Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. Journal of Infectious Diseases, 1999, 180, 1018-1024.	4.0	66
53	Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. Journal of Medical Virology, 2005, 76, 153-160.	5.0	66
54	Seroprevalence of hepatitis B and C viruses among HIVâ€infected pregnant women in Uganda and Rwanda. Journal of Medical Virology, 2007, 79, 1797-1801.	5.0	65

#	Article	IF	Citations
55	Triple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral Load. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 286-291.	2.1	61
56	Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. Journal of Medical Virology, 2003, 69, 1-6.	5.0	59
57	Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIVâ€1â€“Infected Adults: A EuroSIDA Study. Journal of Infectious Diseases, 2004, 190, 148-155.	4.0	58
58	Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 153-160.	0.3	58
59	A â€œsystems medicineâ€•approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.9	56
60	Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. PLoS ONE, 2013, 8, e68950.	2.5	56
61	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA. Journal of Clinical Virology, 2009, 46, 367-370.	3.1	54
62	Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. Aids, 2001, 15, 1269-1274.	2.2	52
63	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virusâ€“Infected Patients with Very Low CD4 Cell Counts. Journal of Infectious Diseases, 2002, 186, 189-197.	4.0	52
64	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. Antiviral Therapy, 2006, 11, 707-716.	1.0	52
65	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	2.2	51
66	Thymus volume correlates with the progression of vertical HIV infection. Aids, 1999, 13, F29-F34.	2.2	49
67	Epidemiology of AIDS-related KaposiÊ¼s sarcoma in Europe over 10 years. Aids, 1996, 10, 911-918.	2.2	48
68	The Reverse Transcription Inhibitor Abacavir Shows Anticancer Activity in Prostate Cancer Cell Lines. PLoS ONE, 2010, 5, e14221.	2.5	48
69	Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. Aids, 2005, 19, 1843-1847.	2.2	47
70	Update on a proteinase inhibitor. Aids, 1994, 8, S25-S30.	2.2	46
71	Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. Aids, 1995, 9, 51-56.	2.2	46
72	Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. Journal of Clinical Virology, 2010, 47, 4-7.	3.1	45

#	Article	IF	Citations
73	EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD. International Journal of Molecular Sciences, 2013, 14, 24154-24168.	4.1	44
74	Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. Aids, 2005, 19, 433-437.	2.2	43
75	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS ONE, 2017, 12, e0172159.	2.5	42
76	Indinavir Pharmacokinetics and Parmacodynamics in Children with Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2000, 44, 752-755.	3.2	41
77	Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. Aids, 2001, 15, 2231-2238.	2.2	41
78	Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Medicine, 2013, 11, 4.	5.5	40
79	Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet, The, 2002, 360, 1710-1711.	13.7	39
80	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. AIDS Patient Care and STDs, 2009, 23, 513-520.	2.5	39
81	Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. British Journal of Cancer, 2013, 109, 2607-2618.	6.4	39
82	AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987â€“93) and differential incidence according to mode of transmission of HIV-1 infection. Journal of the Neurological Sciences, 1996, 144, 107-113.	0.6	38
83	Scaling up antiretroviral therapy in resource-limited settings. Current Opinion in HIV and AIDS, 2013, 8, 12-18.	3.8	38
84	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. Antiviral Therapy, 2012, 17, 1511-1519.	1.0	37
85	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International, 2020, 40, 1545-1555.	3.9	37
86	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	2.5	37
87	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 39-47.	2.1	36
88	Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. Aids, 1998, 12, 473-480.	2.2	35
89	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology, 2015, 12, 4.	2.0	35
90	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLoS ONE, 2014, 9, e87160.	2.5	35

#	Article	IF	Citations
91	Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Research, 1996, 29, 95-97.	4.1	34
92	Causes of death in HIV infection. Aids, 2004, 18, 2333-2337.	2.2	34
93	Birth defects in a national cohort of pregnant women with <scp>HIV</scp> infection in <scp>I</scp>taly, 2001â€“2011. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 1466-1476.	2.3	34
94	Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. Journal of Pediatrics, 1999, 135, 675-682.	1.8	33
95	Single-nucleotide polymorphisms in human Î²-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. Aids, 2008, 22, 1515-1517.	2.2	33
96	The Effect of SEX/Gender on Cardiovascular Pharmacology. Current Pharmaceutical Design, 2011, 17, 1095-1107.	1.9	33
97	Cardiovascular Measures in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Who Are New Users of Methylphenidate and Atomoxetine. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 423-431.	1.3	33
98	Forecasting Hepatitis C liver disease burden on realâ€life data. Does the hidden iceberg matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	3.9	33
99	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 1027-1030.	3.0	32
100	Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. Aids, 2000, 14, 345-355.	2.2	30
101	Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. Aids, 2008, 22, 2381-2390.	2.2	30
102	Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. Antiviral Research, 1998, 37, 1-16.	4.1	29
103	The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. PLoS ONE, 2013, 8, e76582.	2.5	29
104	Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4 + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Research, 1996, 29, 91-93.	4.1	28
105	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. Journal of Clinical Microbiology, 2003, 41, 1760-1762.	3.9	28
106	A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Therapeutic Delivery, 2011, 2, 1437-1453.	2.2	28
107	Retention in Care of Adult HIV Patients Initiating Antiretroviral Therapy in Tigray, Ethiopia: A Prospective Observational Cohort Study. PLoS ONE, 2015, 10, e0136117.	2.5	28
108	ISSQoL: A New Questionnaire for Evaluating the Quality of Life of People Living with HIV in the HAART Era*. Quality of Life Research, 2006, 15, 377-390.	3.1	27

#	Article	IF	Citations
109	Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. Journal of Medical Virology, 1980, 6, 203-211.	5.0	26
110	Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. Biochemical Journal, 2001, 355, 587-595.	3.7	26
111	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE, 2014, 9, e109791.	2.5	26
112	Tuberculosis among European patients with the acquired immune deficiency syndrome. Tubercle and Lung Disease, 1996, 77, 322-328.	2.1	25
113	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 321-330.	2.1	25
114	Deteriorating renal function and clinical outcomes in HIV-positive persons. Aids, 2014, 28, 727-737.	2.2	25
115	Modeling costâ€effectiveness and health gains of a â€œuniversalâ€•versus â€œprioritizedâ€•hepatitis C virus treatment policy in a realâ€life cohort. Hepatology, 2017, 66, 1814-1825.	7.3	25
116	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiologica, 2012, 35, 113-59.	0.1	25
117	Quality of life outcomes of combination zidovudineâ€“didanosineâ€“nevirapine and zidovudineâ€“didanosine for antiretroviral-naive advanced HIV-infected patients. Aids, 2000, 14, 2567-2574.	2.2	24
118	Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. Aids, 2013, 27, 579-589.	2.2	24
119	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. Antiviral Therapy, 2003, 8, 127-136.	1.0	24
120	Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy. Aids, 2000, 14, 939-949.	2.2	23
121	PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. Digestive and Liver Disease, 2015, 47, 741-743.	0.9	23
122	HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*. HIV Medicine, 2002, 3, 75-84.	2.2	22
123	Post-natal stress-induced endocrine and metabolic alterations in mice at adulthood involve different pro-opiomelanocortin-derived peptides. Peptides, 2010, 31, 2123-2129.	2.4	22
124	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	3.0	22
125	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. Antiviral Therapy, 2005, 10, 779-790.	1.0	22
126	Italian Attention-Deficit/Hyperactivity Disorder Registry. Pediatrics, 2004, 114, 514-514.	2.1	21

#	Article	IF	Citations
127	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. Journal of Clinical Microbiology, 2005, 43, 6183-6185.	3.9	21
128	The Effects of AZT and DDI on Pre- and Postimplantation Mammalian Embryos: An In Vivo and In Vitro Study. AIDS Research and Human Retroviruses, 1992, 8, 639-649.	1.1	20
129	In Vitro and In Vivo Modulation of MDR1/P-Glycoprotein in HIV-Infected Patients Administered Highly Active Antiretroviral Therapy and Liposomal Doxorubicin. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 369-378.	2.1	20
130	HIV phenotype switching during antiretroviral therapy. Aids, 1997, 11, 1211-1217.	2.2	19
131	Interleukin-15 enhances the secretion of IFN-Î³ and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunology Letters, 2006, 103, 192-195.	2.5	19
132	Attention-Deficit/Hyperactivity Disorder Drugs and Growth: An Italian Prospective Observational Study. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 440-447.	1.3	19
133	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. Journal of Hepatology, 2018, 68, 33-41.	3.7	19
134	Correlation between Changes in Plasma HIV RNA Levels and in Plasma Infectivity in Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 1997, 13, 555-561.	1.1	18
135	Discordant response to antiretroviral therapy. Aids, 2002, 16, 1877-1885.	2.2	18
136	Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. Aids, 2003, 17, 1570-1572.	2.2	18
137	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. Antimicrobial Agents and Chemotherapy, 2006, 50, 3407-3417.	3.2	18
138	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ¯ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	2.2	18
139	Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity. BMC Biotechnology, 2019, 19, 64.	3.3	18
140	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmuL). HIV Medicine, 2004, 5, 1-10.	2.2	17
141	Using CD4 Percentage and Age to Optimize Pediatric Antiretroviral Therapy Initiation. Pediatrics, 2014, 134, e1104-e1116.	2.1	16
142	AGITATED SLEEPWALKING WITH FLUOROQUINOLONE THERAPY. Pediatric Infectious Disease Journal, 1999, 18, 484-485.	2.0	16
143	Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. Journal of Medical Virology, 2007, 79, 111-117.	5.0	15
144	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. Journal of Virological Methods, 2010, 168, 272-276.	2.1	15

#	Article	IF	Citations
145	Maximizing the benefits of antiretroviral therapy for key affected populations. Journal of the International AIDS Society, 2014, 17, 19320.	3.0	15
146	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. BMC Biotechnology, 2019, 19, 67.	3.3	15
147	Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: The role of age. Journal of Allergy and Clinical Immunology, 2001, 108, 439-445.	2.9	14
148	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. Journal of Clinical Microbiology, 2003, 41, 3007-3012.	3.9	14
149	Dynamic NAD(P)H post-synaptic autofluorescence signals for the assessment of mitochondrial function in a neurodegenerative disease: Monitoring the primary motor cortex of G93A mice, an amyotrophic lateral sclerosis model. Mitochondrion, 2010, 10, 108-114.	3.4	14
150	Predictors of attrition from care at 2 years in a prospective cohort of HIV-infected adults in Tigray, Ethiopia. BMJ Global Health, 2017, 2, e000325.	4.7	14
151	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment1. Antiviral Research, 2000, 47, 189-198.	4.1	13
152	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 816-818.	1.1	13
153	Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substances. Peptides, 2010, 31, 1598-1605.	2.4	13
154	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of motherâ€toâ€infant transmission in Malawi. Journal of Medical Virology, 2012, 84, 1553-1557.	5.0	13
155	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1377-1384.	3.0	13
156	Hospitalizations and Costs of Treatment for Protease Inhibitor-Based Regimens in Patients with Very Advanced HIV-Infection (CD4 < 50/mm3). HIV Clinical Trials, 2000, 1, 9-16.	2.0	12
157	Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients. Clinical Drug Investigation, 2000, 20, 295-307.	2.2	12
158	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Aids, 2013, 27, 907-918.	2.2	12
159	Optimization and simplification of antiretroviral therapy for adults and children. Current Opinion in HIV and AIDS, 2013, 8, 591-599.	3.8	12
160	The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. BMC Infectious Diseases, 2014, 14, 180.	2.9	12
161	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics, 2019, 37, 255-266.	3.3	12
162	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. HIV Clinical Trials, 2008, 9, 287-297.	2.0	11

#	Article	IF	Citations
163	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Medicine, 2009, 10, 477-481.	2.2	11
164	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. HIV Clinical Trials, 2014, 15, 104-115.	2.0	11
165	End of AIDS on the horizon, but innovation needed to end HIV. Lancet HIV,the, 2015, 2, e74-e75.	4.7	11
166	APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz. Frontiers in Immunology, 2018, 9, 1839.	4.8	11
167	Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients. AIDS Research and Human Retroviruses, 1995, 11, 1203-1207.	1.1	10
168	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. Aids, 2007, 21, 2360-2362.	2.2	10
169	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrology, 2014, 15, 51.	1.8	10
170	The Manufacturersâ€™ Perspective on World Health Organization Prequalification of In Vitro Diagnostics. Clinical Infectious Diseases, 2018, 66, 301-305.	5.8	10
171	Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. Value in Health, 2018, 21, 783-791.	0.3	10
172	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1809-1820.	1.1	9
173	Mission now possible for AIDS fund. Nature, 2001, 412, 271-272.	27.8	9
174	Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. Journal of Antimicrobial Chemotherapy, 2004, 53, 494-500.	3.0	9
175	Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. Clinical and Experimental Immunology, 2004, 135, 280-285.	2.6	9
176	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. AIDS Research and Human Retroviruses, 2009, 25, 707-711.	1.1	9
177	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. AIDS Research and Human Retroviruses, 2016, 32, 737-742.	1.1	9
178	Circulating Antineutrophil Autoantibodies in a Child with Isolated Central Nervous System Vasculitis. Neuropediatrics, 1999, 30, 268-269.	0.6	8
179	Selection of Resistance Mutations in Children Receiving Prophylaxis With Lamivudine or Nevirapine for the Prevention of Postnatal Transmission of HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 131-133.	2.1	8
180	Antiretroviral Resistance Mutations in Untreated Pregnant Women with HIV Infection in Uganda and Rwanda. AIDS Research and Human Retroviruses, 2007, 23, 1449-1451.	1.1	8

#	Article	IF	Citations
181	Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells. BMC Pharmacology & Toxicology, 2013, 14, 47.	2.4	8
182	Commentary. Aids, 2014, 28, S101-S104.	2.2	8
183	Addressing barriers to the end of AIDS by 2030. Lancet HIV,the, 2015, 2, e360-e361.	4.7	8
184	Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi. International Journal of STD and AIDS, 2016, 27, 462-468.	1.1	8
185	Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi. Infectious Diseases, 2017, 49, 708-711.	2.8	8
186	Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. Aids, 2015, 30, 1.	2.2	8
187	Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. European Journal of Epidemiology, 1998, 14, 41-47.	5.7	7
188	Modification of cell perifusion for extended study of hormone release in the rat pituitary. Cytotechnology, 2001, 23, 197-204.	0.7	7
189	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. AIDS Research and Human Retroviruses, 2010, 26, 541-545.	1.1	7
190	Enhanced brain performance in mice following postnatal stress. Journal of Endocrinology, 2012, 215, 413-424.	2.6	7
191	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	3.0	7
192	Host and disease factors are associated with cognitive function in European <scp>HIV</scp>â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	2.2	7
193	CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding. Medical Microbiology and Immunology, 2017, 206, 23-29.	4.8	7
194	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	3.0	7
195	A Randomized Controlled Study for the Evaluation of the Activity of a Triple Combination of Zidovudine, Thymosin-Î±1 and Interferon-Î± in HIV-Infected Individuals with CD4 Counts between 200 and 500 cells/mm3. Antiviral Therapy, 1998, 3, 103-111.	1.0	7
196	Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent. Aids, 1998, 12, 2185-2192.	2.2	6
197	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. HIV Clinical Trials, 2007, 8, 182-188.	2.0	6
198	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine, 2012, 57, 54-60.	3.2	6

#	Article	IF	Citations
199	Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS and Behavior, 2013, 17, 193-202.	2.7	6
200	Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. AIDS Research and Therapy, 2016, 13, 18.	1.7	6
201	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. Infectious Diseases, 2016, 48, 317-321.	2.8	6
202	Tumor Necrosis Factor-Î±, Interleukin-10, and Î±-Defensins in Plasma and Breast Milk of HIV-Infected Highly Active Antiretroviral Therapy-Treated and Untreated Pregnant Women in Mozambique. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 647-649.	2.1	5
203	Levels of bone markers in a population of infants exposedin uteroand during breastfeeding to tenofovir within an Option B+ programme in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 3206-3211.	3.0	5
204	Access to medicines: lessons from the HIV response. Lancet HIV,the, 2017, 4, e147-e149.	4.7	5
205	Antibody response to hepatitis B vaccine in HIVâ€exposed infants in Malawi and correlation with HBV infection acquisition. Journal of Medical Virology, 2018, 90, 1172-1176.	5.0	5
206	Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated <scp>HCV</scp>â€related condition in the real life practice. Liver International, 2018, 38, 183-183.	3.9	5
207	Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 519-526.	2.1	5
208	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV,the, 2019, 6, e334-e340.	4.7	5
209	Apoptotic Cell Signaling in Lymphocytes from HIV+ Patients during Successful Therapy. Annals of the New York Academy of Sciences, 2006, 1090, 130-137.	3.8	4
210	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 68-71.	2.1	4
211	HIV-1 coreceptor switch during 2Âyears of structured treatment interruptions. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1565-1570.	2.9	4
212	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. HIV Clinical Trials, 2013, 14, 110-119.	2.0	4
213	Viral Sequence Analysis of HIV-Positive Women and Their Infected Children: Insight on the Timing of Infection and on the Transmission Network. AIDS Research and Human Retroviruses, 2014, 30, 1010-1015.	1.1	4
214	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. Journal of Interferon and Cytokine Research, 2014, 34, 35-40.	1.2	4
215	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection, 2014, 42, 757-762.	4.7	4
216	Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. Journal of Antimicrobial Chemotherapy, 2015, 70, 2881-2884.	3.0	4

#	Article	IF	Citations
217	From Durban to Durban: end of AIDS further than hoped. Lancet HIV,the, 2016, 3, e403-e405.	4.7	4
218	Soluble <scp>CD</scp>14 levels in plasma and breastmilk of Malawian <scp>HIV</scp>+ women: Lack of association with morbidity and mortality in their exposed infants. American Journal of Reproductive Immunology, 2018, 79, e12812.	1.2	4
219	CD4+Lymphocyte Increases in HIV Patients during Potent Antiretroviral Therapy Are Dependent on Inhibition of CD8+Cell Apoptosis. Annals of the New York Academy of Sciences, 2003, 1010, 560-564.	3.8	3
220	Antisense versus proopiomelanocortin mRNA reduces vascular risk in a murine model of type-2 diabetes following stress exposure in early post-natal life. Peptides, 2015, 64, 34-39.	2.4	3
221	Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. Clinical Microbiology and Infection, 2017, 23, 491-492.	6.0	3
222	High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women. Journal of Clinical Virology, 2017, 96, 17-19.	3.1	3
223	Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression. Aids, 2001, 15, 1178-1181.	2.2	3
224	Health and Climate Change: science calls for global action. Annali Dell'Istituto Superiore Di Sanita, 2019, 55, 323-329.	0.4	3
225	HIV eradication revisited. Expert Opinion on Investigational Drugs, 2000, 9, 193-197.	4.1	2
226	Success hinges on support for treatment. Nature, 2001, 412, 272-272.	27.8	2
227	Future Treatment Perspectives. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, S95-S100.	2.1	2
228	Absence of Unfavorable Effect of Atomoxetine on Growth in Pediatric Patients Is Still Not Demonstrated. Pediatrics, 2006, 117, 587-588.	2.1	2
229	Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. AIDS Patient Care and STDs, 2009, 23, 147-152.	2.5	2
230	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. Journal of Antimicrobial Chemotherapy, 2014, 69, 749-752.	3.0	2
231	Unite forces to validate biomarkers in the quest for lasting HIV remission. Aids, 2016, 30, 1859-1860.	2.2	2
232	Isolation and preliminary characterization of a human â€˜phage displayâ€™-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding. Human Antibodies, 2021, 29, 63-84.	1.5	2
233	Anti-Streptococcus pneumoniae and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. Journal of Medical Microbiology, 2015, 64, 795-797.	1.8	2
234	Antiretroviral drug resistance and HIV/AIDS in the developing world. Journal of HIV Therapy, 2002, 7, 53-5.	0.6	2

#	Article	IF	Citations
235	Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. , 1998, 56, 332-336.		1
236	British HIV Association guidelines. Lancet, The, 1998, 352, 1226-1227.	13.7	1
237	Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. Journal of Medical Microbiology, 2009, 58, 121-124.	1.8	1
238	The Absence of HIV Mutations in Cerebrospinal Fluid and in Peripheral Blood Mononuclear Cells During a Regimen Containing Trizivir Plus Tenofovir. Journal of Chemotherapy, 2009, 21, 455-457.	1.5	1
239	Treatment as Prevention: unanswered questions and progress to date. Journal of the International AIDS Society, 2014, 17, 19521.	3.0	1
240	Weight Changes During and After 6 Months of Breastfeeding in HIV-Infected Mothers Receiving Antiretroviral Therapy in Malawi. AIDS Research and Human Retroviruses, 2014, 30, 1155-1157.	1.1	1
241	HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. Digestive and Liver Disease, 2016, 48, e6-e7.	0.9	1
242	Access to HIV/AIDS Care and Treatment in the South of the World. Aids, 2001, 15, IAS1-IAS3.	2.2	1
243	HIV treatment - a rational approach to the use of antiretroviral agents. Haemophilia, 1998, 4, 616-618.	2.1	0
244	hu-SCID: A model for the evaluation of vaginal microbicides. Aids, 2001, 15, S19.	2.2	0
245	Targeting CCL2 inhibits viral DNA accumulation and induces APOBEC3A expression in HIV-1 infected primary human macrophages. Retrovirology, 2013, 10, .	2.0	0
246	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. Clinical Infectious Diseases, 2013, 56, 1190-1193.	5.8	0
247	Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi. Journal of Tropical Pediatrics, 2015, 61, 222-225.	1.5	0
248	Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e90-e91.	2.1	0
249	First-line HIV therapy shall not fail. Lancet HIV,the, 2016, 3, e108-e109.	4.7	0
250	Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data. Journal of Virus Eradication, 2018, 4, 25-26.	0.5	0
251	Immunoterapia del cancro. Global & Regional Health Technology Assessment, 2016, 3, S1-S2.	0.1	0
252	HIV clinical research in developing countries: challenges and priorities. Journal of HIV Therapy, 2004, 9, 49.	0.6	0

#	Article	IF	Citations
253	Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?. Journal of HIV Therapy, 2003, 8, 27-8.	0.6	0